lorazepam has been researched along with Anxiety Neuroses in 97 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ritanserin, (20 mg daily) and lorazepam (5 mg daily) were administered to 24 patients suffering from generalized anxiety disorders (DSM III), in a double-blind fashion for six weeks." | 9.06 | Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. ( Bressa, GM; Gregori, S; Marini, S, 1987) |
| "The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam." | 7.71 | De novo absence status of late onset following withdrawal of lorazepam: a case report. ( Fernández-Torre, JL, 2001) |
| "After the preliminary successful use of injectable lorazepam in calming 20 patients who presented with acute anxiety crises, a formal study of 115 other such patients was carried out." | 7.66 | Management of acute anxiety syndrome with parenterally administered lorazepam. ( Gómez-Lozano, P, 1978) |
| "Panic attacks were defined using the panic symptom scale (PSS)." | 6.76 | One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI. ( Demazières, A; Erb, G; Hode, Y; Luthringer, R; Mathis, A; Namer, IJ; Schunck, T, 2011) |
| " Therapeutically effective dosage was 3." | 6.71 | [Spectrum of therapeutic efficacy and safety of Lorafen (lorazepam) use for anxiety disorders]. ( Burlakov, AV; Il'ina, NA; Ivanov, SV, 2003) |
| " Ritanserin, (20 mg daily) and lorazepam (5 mg daily) were administered to 24 patients suffering from generalized anxiety disorders (DSM III), in a double-blind fashion for six weeks." | 5.06 | Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. ( Bressa, GM; Gregori, S; Marini, S, 1987) |
| "The antipanic efficacy of alprazolam and lorazepam was evaluated in 48 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder in a double-blind random assignment study." | 5.06 | Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. ( Charney, DS; Woods, SW, 1989) |
| "Lorazepam is effective and safe preparation for the treatment of anxiety disorders in patients with IHD." | 3.73 | [Effect of Lorazepam on emotional status and quality of life of patients with ischemic heart disease]. ( Ibatov, AD, 2006) |
| "The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam." | 3.71 | De novo absence status of late onset following withdrawal of lorazepam: a case report. ( Fernández-Torre, JL, 2001) |
| " The authors present three patients with alcoholism in whom diagnosis of panic was facilitated by intravenous lactate infusion, and whose symptoms were alleviated by clonazepam." | 3.68 | The diagnosis and treatment of panic disorder in alcoholics: three cases. ( Baron, DH; Ciraulo, DA; Sands, BF; Shader, RI, 1990) |
| "After the preliminary successful use of injectable lorazepam in calming 20 patients who presented with acute anxiety crises, a formal study of 115 other such patients was carried out." | 3.66 | Management of acute anxiety syndrome with parenterally administered lorazepam. ( Gómez-Lozano, P, 1978) |
| "A clinical study was carried out in 73 neoplastic patients suffering from anxiety and other emotional upsets to assess the effectiveness and tolerance of lorazepam." | 3.65 | Anxiety therapy in the neoplastic patient. ( Battelli, T; Bonsignori, M; Manocchi, P; Rossi, G, 1976) |
| "Change in anxiety was evaluated as a function of medication, disorder, time, potency, lipophilicity, and standardized dose and compared among benzodiazepines." | 3.01 | Pharmacologic predictors of benzodiazepine response trajectory in anxiety disorders: a Bayesian hierarchical modeling meta-analysis. ( Mills, JA; Stimpfl, JN; Strawn, JR, 2023) |
| "Anxiety is common among persons with alcohol use disorder during early abstinence from alcohol." | 2.82 | Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study. ( Bhatt, S; Bogenschutz, MP; Bohan, J; Foster, B; Romo, P; Tonigan, JS; Wilcox, CE, 2016) |
| " Results from the PET study indicated that the L-759274 dosing regimen used in the clinical trial likely provided high levels of NK1 receptor occupancy (>90%), supporting the view that it was an adequate proof-of-concept trial." | 2.78 | Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. ( Alexander, R; Ceesay, P; Hargreaves, R; Hietala, J; Lines, C; Michelson, D; Reines, S, 2013) |
| "Panic attacks were defined using the panic symptom scale (PSS)." | 2.76 | One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI. ( Demazières, A; Erb, G; Hode, Y; Luthringer, R; Mathis, A; Namer, IJ; Schunck, T, 2011) |
| " Therapeutically effective dosage was 3." | 2.71 | [Spectrum of therapeutic efficacy and safety of Lorafen (lorazepam) use for anxiety disorders]. ( Burlakov, AV; Il'ina, NA; Ivanov, SV, 2003) |
| "Fifteen healthy volunteers participated in a double-blind, placebo-controlled, randomized dose-response study." | 2.71 | Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. ( Castillo, G; Feinstein, JS; Paulus, MP; Simmons, AN; Stein, MB, 2005) |
| "Lorazepam treatment resulted in descriptively, but not significantly, greater improvement on the Hamilton Rating Scale for Anxiety during the whole treatment (week 0-4) and taper period (week 5, 6) than did buspirone." | 2.69 | Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. ( Baghai, T; Ehrentraut, S; Kuhn, K; Laakmann, G; Lorkowski, G; Schüle, C, 1998) |
| " Side effects were assessed through the Dosage Treatment Emergent Symptoms at the same times." | 2.68 | Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. ( Casacchia, M; Delle Chiaie, R; Kotzalidis, GD; Pancheri, P; Stratta, P; Zibellini, M, 1995) |
| "Physicians' global evaluation of insomnia demonstrated no changes in the pre-drug placebo period, moderate improvement under both drugs, with a marginal advantage of SOM over LOR in the first 2 weeks, and a return to pre-drug values in the post-drug placebo period." | 2.68 | Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping meth ( Anderer, P; Brandstätter, N; Frey, R; Gruber, G; Grünberger, J; Klösch, G; Linzmayer, L; Mandl, M; Saletu, B; Saletu-Zyhlarz, G, 1997) |
| "Buspirone was compared to alprazolam and lorazepam in the treatment of generalized anxiety disorder in a 4-week, double-blind study of 60 patients." | 2.66 | Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. ( Cohn, JB; Wilcox, CS, 1986) |
| "The lorazepam-treated group showed significantly greater improvement than the placebo-treated group (both clinically and statistically), as evidenced by the greater changes on the physician-rated Global Scale as well as by the greater changes in almost all categories on the physician-rated Hamilton Anxiety Scale and the patient-rated Lipman-Rickels 35-Item Self-Rating Scale." | 2.64 | Clinical assessment of the safety and efficacy of lorazepam, a new benzodiazepine derivative, in the treatment of anxiety. ( Pinosky, DG, 1978) |
| " Average dosage was 3 mg/day given as 2 mg in the evening and 1 mg in the morning." | 2.64 | Antianxiety effects of lorazepam in patients with cardiovascular symptomatology. ( Finkel, S, 1978) |
| "lorazepam; 6 weeks), and in restlessness and agitation (vs." | 2.46 | Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials. ( Dienel, A; Gastpar, M; Kasper, S; Möller, HJ; Müller, WE; Schläfke, S; Volz, HP, 2010) |
| "Lormetazepam was more frequently consumed by females with a high school education, having a psychiatric disorder, taken in drops and prescribed for insomnia." | 1.43 | Socio-demographic and clinical characteristics of benzodiazepine long-term users: Results from a tertiary care center. ( Casari, R; Cosci, F; Faccini, M; Lugoboni, F; Mansueto, G, 2016) |
| "However in those cases withdrawal symptoms were distinct and the medical intervention was needed." | 1.38 | [Description of a patient with schizophrenia and coexisting megadose lorazepam dependence with slightly expressed withdrawl symptoms during drug reduction. A case report]. ( Badura-Brzoza, K; Pasierb, N; Schylla, A; Scisło, P, 2012) |
| "Catatonia is a well-described neuropsychiatric syndrome that has been the subject of several texts." | 1.37 | Cases of catatonia on an academic electroconvulsive therapy service: lessons to learn. ( Aloysi, AS; Kellner, CH; Popeo, DM, 2011) |
| " A dose-response effect was evident for PGB that reached a plateau at a dose of 300 mg/d." | 1.36 | Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. ( Feltner, DE; Herman, B; Lydiard, RB; Rickels, K, 2010) |
| " Caution should be exercised in long-term use of benzodiazepines in susceptible individuals." | 1.27 | Delusional depression following benzodiazepine withdrawal. ( Eales, M; Joyce, E; Keshavan, MS; Moodley, P; Yeragani, VK, 1988) |
| "The benzodiazepine withdrawal symptoms are presented here." | 1.27 | Manic-like reaction induced by lorazepam withdrawal. ( Labelle, A; Lapierre, YD, 1987) |
| " Subsequent administration of an equivalent dosage of lorazepam did not induce manic symptoms." | 1.27 | A case of alprazolam, but not lorazepam, inducing manic symptoms. ( Charney, DS; Goodman, WK, 1987) |
| " Firstly, there is a body of research which has shown problems of dependence and habituation in the long-term use of anti-anxiety drugs." | 1.27 | A controlled trial of treatments for generalized anxiety. ( Espie, CA; Gamsu, CV; Hood, EM; Lindsay, WR; McLaughlin, E, 1987) |
| "lorazepam t." | 1.25 | Treatment of 'brain fag' syndrome. ( Anumonye, A, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (45.36) | 18.7374 |
| 1990's | 20 (20.62) | 18.2507 |
| 2000's | 16 (16.49) | 29.6817 |
| 2010's | 15 (15.46) | 24.3611 |
| 2020's | 2 (2.06) | 2.80 |
| Authors | Studies |
|---|---|
| Stimpfl, JN | 1 |
| Mills, JA | 1 |
| Strawn, JR | 1 |
| Yap, WS | 1 |
| Dolzhenko, AV | 1 |
| Jalal, Z | 1 |
| Hadi, MA | 1 |
| Khan, TM | 1 |
| Haddad, PM | 1 |
| Al Abdulla, M | 1 |
| Latoo, J | 1 |
| Iqbal, Y | 1 |
| Perkins, AM | 1 |
| Ettinger, U | 1 |
| Weaver, K | 1 |
| Schmechtig, A | 1 |
| Schrantee, A | 1 |
| Morrison, PD | 1 |
| Sapara, A | 1 |
| Kumari, V | 1 |
| Williams, SC | 1 |
| Corr, PJ | 1 |
| Schylla, A | 1 |
| Scisło, P | 1 |
| Badura-Brzoza, K | 1 |
| Pasierb, N | 1 |
| Kasper, S | 2 |
| Iglesias-García, C | 1 |
| Schweizer, E | 3 |
| Wilson, J | 1 |
| DuBrava, S | 1 |
| Prieto, R | 1 |
| Pitman, VW | 1 |
| Knapp, L | 1 |
| Bogenschutz, MP | 1 |
| Bhatt, S | 1 |
| Bohan, J | 1 |
| Foster, B | 1 |
| Romo, P | 1 |
| Wilcox, CE | 1 |
| Tonigan, JS | 1 |
| Brady, KT | 1 |
| Cosci, F | 1 |
| Mansueto, G | 1 |
| Faccini, M | 1 |
| Casari, R | 1 |
| Lugoboni, F | 1 |
| Feltner, DE | 2 |
| Harness, J | 2 |
| Brock, J | 1 |
| Sambunaris, A | 1 |
| Cappelleri, JC | 2 |
| Morlock, R | 1 |
| Lydiard, RB | 2 |
| Rickels, K | 4 |
| Herman, B | 1 |
| Woelk, H | 1 |
| Schläfke, S | 2 |
| Schunck, T | 1 |
| Mathis, A | 1 |
| Erb, G | 1 |
| Namer, IJ | 1 |
| Hode, Y | 1 |
| Demazières, A | 1 |
| Luthringer, R | 1 |
| Williams, VS | 2 |
| Morlock, RJ | 2 |
| Feltner, D | 2 |
| Gastpar, M | 1 |
| Müller, WE | 1 |
| Volz, HP | 1 |
| Möller, HJ | 1 |
| Dienel, A | 1 |
| Aloysi, AS | 1 |
| Popeo, DM | 1 |
| Kellner, CH | 1 |
| Michelson, D | 1 |
| Hargreaves, R | 1 |
| Alexander, R | 1 |
| Ceesay, P | 1 |
| Hietala, J | 1 |
| Lines, C | 1 |
| Reines, S | 1 |
| Herrera-Arellano, A | 2 |
| Jiménez-Ferrer, JE | 1 |
| Zamilpa, A | 2 |
| García-Alonso, G | 1 |
| Herrera-Alvarez, S | 1 |
| Tortoriello, J | 2 |
| Curtin, F | 1 |
| Redmund, C | 1 |
| Ivanov, SV | 1 |
| Il'ina, NA | 1 |
| Burlakov, AV | 1 |
| Paulus, MP | 1 |
| Feinstein, JS | 1 |
| Castillo, G | 1 |
| Simmons, AN | 1 |
| Stein, MB | 1 |
| Stewart, SA | 1 |
| Videla, S | 1 |
| Sust, M | 1 |
| Fresquet, A | 1 |
| Villoria, J | 1 |
| Kruszewski, SP | 1 |
| Bailey, JE | 1 |
| Kendrick, A | 1 |
| Diaper, A | 1 |
| Potokar, JP | 1 |
| Nutt, DJ | 1 |
| Ibatov, AD | 1 |
| Jiménez-Ferrer, E | 1 |
| Morales-Valdéz, M | 1 |
| García-Valencia, CE | 1 |
| Fehnel, SE | 1 |
| Endicott, J | 1 |
| Carroll, BT | 1 |
| Thomas, C | 1 |
| Tugrul, KC | 1 |
| Coconcea, C | 1 |
| Goforth, HW | 1 |
| Zung, WW | 1 |
| Daniel, JT | 1 |
| King, RE | 1 |
| Moore, DT | 1 |
| Ameer, B | 1 |
| Greenblatt, DJ | 2 |
| Fouks, L | 1 |
| Widlocher, D | 1 |
| Lecrubier, Y | 1 |
| Le Goc, Y | 1 |
| Ruiz, AT | 1 |
| Ananth, J | 1 |
| Van den Steen, N | 1 |
| Danion, JM | 1 |
| Brion, S | 1 |
| Escande, M | 1 |
| Ropert, R | 1 |
| Sacquepee, L | 1 |
| Singer, L | 1 |
| Scotto, JC | 1 |
| Romach, M | 1 |
| Busto, U | 1 |
| Somer, G | 1 |
| Kaplan, HL | 1 |
| Sellers, E | 1 |
| Louvel, D | 1 |
| Delvaux, M | 1 |
| Larrue, V | 1 |
| Moreau, J | 1 |
| Bonnafous, C | 1 |
| Bueno, L | 1 |
| Frexinos, J | 1 |
| Delle Chiaie, R | 1 |
| Pancheri, P | 1 |
| Casacchia, M | 1 |
| Stratta, P | 1 |
| Kotzalidis, GD | 1 |
| Zibellini, M | 1 |
| O'Hanlon, JF | 1 |
| Vermeeren, A | 1 |
| Uiterwijk, MM | 1 |
| van Veggel, LM | 1 |
| Swijgman, HF | 1 |
| Cohen, SI | 1 |
| Cutler, NR | 2 |
| Sramek, JJ | 2 |
| Wardle, TS | 1 |
| Hesselink, JM | 1 |
| Roeschen, JK | 1 |
| Keppel Hesselink, JM | 2 |
| Krol, A | 1 |
| Roeschen, J | 2 |
| Deckert, J | 1 |
| Przuntek, H | 1 |
| Gleiter, CH | 1 |
| Bourin, M | 2 |
| Malinge, M | 1 |
| Cirimele, V | 1 |
| Kintz, P | 1 |
| Mangin, P | 1 |
| Mandos, LA | 1 |
| Cutler, N | 1 |
| Saletu, B | 2 |
| Saletu-Zyhlarz, G | 2 |
| Anderer, P | 1 |
| Brandstätter, N | 1 |
| Frey, R | 2 |
| Gruber, G | 1 |
| Klösch, G | 1 |
| Mandl, M | 1 |
| Grünberger, J | 2 |
| Linzmayer, L | 2 |
| Böck, G | 1 |
| Weissgram, S | 1 |
| Brandstaätter, N | 1 |
| Laakmann, G | 1 |
| Schüle, C | 1 |
| Lorkowski, G | 1 |
| Baghai, T | 1 |
| Kuhn, K | 1 |
| Ehrentraut, S | 1 |
| Garcia, C | 1 |
| Micallef, J | 1 |
| Dubreuil, D | 1 |
| Philippot, P | 1 |
| Jouve, E | 1 |
| Blin, O | 1 |
| Tsoh, JM | 1 |
| Leung, HC | 1 |
| Ungvari, GS | 1 |
| Lee, DT | 1 |
| Bentué-Ferrer, D | 1 |
| Reymann, JM | 1 |
| Tribut, O | 1 |
| Allain, H | 1 |
| Vasar, E | 1 |
| Fernández-Torre, JL | 1 |
| Sim, M | 1 |
| Bindman, E | 1 |
| Morrison, I | 1 |
| Sandilands, D | 1 |
| Ananth, V | 1 |
| Beszterczy, A | 1 |
| Geagea, C | 1 |
| Gomez-Lozano, P | 2 |
| Battelli, T | 1 |
| Bonsignori, M | 1 |
| Manocchi, P | 1 |
| Rossi, G | 1 |
| Lameiras, JC | 1 |
| Walsh, MR | 1 |
| Dunckley, HG | 1 |
| Sinclair, JM | 1 |
| Schiff, AA | 1 |
| Andreoli, V | 1 |
| Maffei, F | 1 |
| Montanaro, N | 1 |
| Morandini, G | 1 |
| Pinosky, DG | 1 |
| McCurdy, L | 1 |
| Schatzberg, AF | 1 |
| Finkel, S | 1 |
| Richards, DJ | 1 |
| Adler, F | 1 |
| Andrews, D | 1 |
| Olgiati, SG | 1 |
| Anumonye, A | 1 |
| Morton, S | 1 |
| Lader, M | 1 |
| Benazzi, F | 1 |
| Laws, D | 1 |
| Ashford, JJ | 1 |
| Anstee, JA | 1 |
| Feder, R | 1 |
| Petracca, A | 1 |
| Nisita, C | 1 |
| McNair, D | 1 |
| Melis, G | 1 |
| Guerani, G | 1 |
| Cassano, GB | 1 |
| Baron, DH | 1 |
| Sands, BF | 1 |
| Ciraulo, DA | 1 |
| Shader, RI | 1 |
| Itil, T | 1 |
| Shapiro, D | 1 |
| Itil, KZ | 1 |
| Eralp, E | 1 |
| Bergamo, M | 1 |
| Mucci, A | 1 |
| Bodkin, JA | 1 |
| White, K | 1 |
| Howell, EF | 1 |
| Laraia, MT | 1 |
| Fossey, MD | 1 |
| Ballenger, JC | 1 |
| Charney, DS | 2 |
| Woods, SW | 1 |
| Fontaine, R | 2 |
| Annable, L | 2 |
| Beaudry, P | 2 |
| Mercier, P | 2 |
| Chouinard, G | 2 |
| Cordingley, GJ | 1 |
| Dean, BC | 1 |
| Hallett, C | 1 |
| Newton, RE | 1 |
| Marunycz, JD | 1 |
| Alderdice, MT | 1 |
| Napoliello, MJ | 1 |
| Cohn, JB | 1 |
| Wilcox, CS | 1 |
| de Leo, D | 1 |
| Ceccarelli, G | 1 |
| Fox, IL | 1 |
| Sandler, KR | 1 |
| Schless, A | 1 |
| Bressa, GM | 1 |
| Marini, S | 1 |
| Gregori, S | 1 |
| Keshavan, MS | 1 |
| Moodley, P | 1 |
| Eales, M | 1 |
| Joyce, E | 1 |
| Yeragani, VK | 1 |
| Khandelwal, SK | 1 |
| Lapierre, YD | 1 |
| Labelle, A | 1 |
| Sandyk, R | 1 |
| Goodman, WK | 1 |
| Lindsay, WR | 1 |
| Gamsu, CV | 1 |
| McLaughlin, E | 1 |
| Hood, EM | 1 |
| Espie, CA | 1 |
| Ceulemans, DL | 1 |
| Hoppenbrouwers, ML | 1 |
| Gelders, YG | 1 |
| Reyntjens, AJ | 1 |
| Ellison, JM | 1 |
| Muskin, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder[NCT00624780] | Phase 4 | 615 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Effects of Lavender Oil on Postoperative Pain, Sleep Quality and Mood[NCT03093454] | Phase 3 | 58 participants (Actual) | Interventional | 2017-10-27 | Completed | ||
| Electroacupuncture Frequency-related Effects on Chronic Low Back Pain in Older Adults: Triple-blind, 12-month Protocol for a Randomized Controlled Trial.[NCT03802045] | 125 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | |||
| Interest of Acupressing in the Treatment of Preoperative Anxiety and Comfort of Patients Undergoing Oocyte Retrieval in Outpatient Surgery[NCT05815121] | 82 participants (Anticipated) | Interventional | 2023-02-09 | Recruiting | |||
| Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety. Double Blind and Randomized Clinical Trial Controlled With Alprazolam[NCT03702803] | Phase 2 | 122 participants (Anticipated) | Interventional | 2016-03-16 | Recruiting | ||
| Magnetic Resonance-guided Focused Ultrasound Ablation of the Anterior Thalamus as a Novel Treatment Paradigm for Anxiety[NCT05032105] | Phase 1 | 10 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | ||
| Randomized, Double-blind, Placebo-controlled Study of a Benzodiazepine vs Placebo on Functional Magnetic Resonance Imaging (fMRI) of the Brain, and on Behavioral/Clinical Measures in Patients With Generalized Anxiety Disorder[NCT00662259] | Phase 4 | 32 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence[NCT00570388] | 120 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -2.3 |
| Pregabalin Low Dose | -2.1 |
| Lorazepam | -2.1 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected (NCT00624780)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | -2.4 |
| Pregabalin High Dose, Placebo | -2.3 |
| Pregabalin Low Dose, Pregabalin Low Dose | -2.4 |
| Pregabalin Low Dose, Placebo | -2.0 |
| Lorazepam, Lorazepam | -2.5 |
| Lorazepam, Placebo | -2.2 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -12.0 |
| Pregabalin Low Dose | -5.9 |
| Lorazepam | -9.7 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -15.6 |
| Pregabalin Low Dose | -14.9 |
| Lorazepam | -16.0 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | -16.6 |
| Pregabalin High Dose, Placebo | -19.1 |
| Pregabalin Low Dose, Pregabalin Low Dose | -18.3 |
| Pregabalin Low Dose, Placebo | -16.0 |
| Lorazepam, Lorazepam | -16.7 |
| Lorazepam, Placebo | -18.7 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -17.4 |
| Pregabalin Low Dose | -16.0 |
| Lorazepam | -16.7 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | -18.7 |
| Pregabalin High Dose, Placebo | -17.5 |
| Pregabalin Low Dose, Pregabalin Low Dose | -18.2 |
| Pregabalin Low Dose, Placebo | -14.9 |
| Lorazepam, Lorazepam | -19.0 |
| Lorazepam, Placebo | -17.5 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -2.0 |
| Pregabalin Low Dose | -2.7 |
| Lorazepam | -3.2 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | 2.1 |
| Pregabalin Low Dose | 2.0 |
| Lorazepam | 1.6 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | 2.8 |
| Pregabalin High Dose, Placebo | -1.0 |
| Pregabalin Low Dose, Pregabalin Low Dose | 1.7 |
| Pregabalin Low Dose, Placebo | 1.8 |
| Lorazepam, Lorazepam | 2.2 |
| Lorazepam, Placebo | -0.1 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. (NCT00624780)
Timeframe: Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | 1.9 |
| Pregabalin Low Dose | 1.9 |
| Lorazepam | 1.9 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. (NCT00624780)
Timeframe: Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | 1.7 |
| Pregabalin High Dose, Placebo | 1.9 |
| Pregabalin Low Dose, Pregabalin Low Dose | 1.6 |
| Pregabalin Low Dose, Placebo | 2.3 |
| Lorazepam, Lorazepam | 1.5 |
| Lorazepam, Placebo | 2.0 |
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | participants (Number) |
|---|---|
| Pregabalin High Dose | 1 |
| Pregabalin Low Dose | 5 |
| Lorazepam | 1 |
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | participants (Number) |
|---|---|
| Pregabalin High Dose | 3 |
| Pregabalin Low Dose | 1 |
| Lorazepam | 2 |
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | participants (Number) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | 4 |
| Pregabalin High Dose, Placebo | 0 |
| Pregabalin Low Dose, Pregabalin Low Dose | 0 |
| Pregabalin Low Dose, Placebo | 1 |
| Lorazepam, Lorazepam | 6 |
| Lorazepam, Placebo | 0 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=15,19,21) | Change at Discontinuation Week 1 (n=15,19,18) | |
| Lorazepam | 24.4 | -9.9 |
| Pregabalin High Dose | 25.8 | -7.7 |
| Pregabalin Low Dose | 24.9 | -5.9 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Discontinuation Week 1 | |
| Lorazepam | 24.6 | -15.8 |
| Pregabalin High Dose | 25.0 | -15.3 |
| Pregabalin Low Dose | 24.7 | -15.3 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Discontinuation Week 1 | |
| Lorazepam, Lorazepam | 24.6 | -16.2 |
| Lorazepam, Placebo | 24.9 | -19.1 |
| Pregabalin High Dose, Placebo | 24.2 | -18.7 |
| Pregabalin High Dose, Pregabalin High Dose | 25.5 | -17.6 |
| Pregabalin Low Dose, Placebo | 24.9 | -16.5 |
| Pregabalin Low Dose, Pregabalin Low Dose | 24.7 | -18.4 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (n=14,19,21) | Change at Discontinuation Week 1 (n=14,19,18) | Change at Discontinuation Week 2 (n=13,15,16) | |
| Lorazepam | 16.4 | -5.9 | -5.4 |
| Pregabalin High Dose | 13.6 | -3.4 | -4.7 |
| Pregabalin Low Dose | 17.6 | -3.3 | -2.7 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (n=57,51,52) | Change at Discontinuation Week 1 (n=57,51,49) | Change at Discontinuation Week 2 (n=53,48,44) | |
| Lorazepam | 14.8 | -7.6 | -8.0 |
| Pregabalin High Dose | 17.4 | -8.5 | -8.3 |
| Pregabalin Low Dose | 17.1 | -9.3 | -8.7 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (n=109,30,94,29,99,30) | Change at DC Week 1 (n=109,30,94,29,99,30) | Change at DC Week 2 (n=106,29,84,26,92,30) | |
| Lorazepam, Lorazepam | 16.8 | -8.7 | -9.6 |
| Lorazepam, Placebo | 14.9 | -10.4 | -10.3 |
| Pregabalin High Dose, Placebo | 17.8 | -12.9 | -13.8 |
| Pregabalin High Dose, Pregabalin High Dose | 17.8 | -11.0 | -9.8 |
| Pregabalin Low Dose, Placebo | 17.4 | -9.9 | -10.2 |
| Pregabalin Low Dose, Pregabalin Low Dose | 16.1 | -11.0 | -10.8 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Last visit on treatment (n=15,18,20) | Change at Discontinuation Week 1 (n=15,18,18) | Change at Discontinuation Week 2 (n=14,15,16) | |
| Lorazepam | 16.1 | -2.4 | -2.2 |
| Pregabalin High Dose | 16.1 | 2.0 | -2.3 |
| Pregabalin Low Dose | 21.6 | -2.3 | -3.5 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Last visit on treatment (n=58,52,50) | Change at Discontinuation Week 1 (n=58,52,48) | Change at Discontinuation Week 2 (n=54,49,44) | |
| Lorazepam | 6.7 | 2.3 | 1.5 |
| Pregabalin High Dose | 8.0 | 1.7 | 1.5 |
| Pregabalin Low Dose | 8.5 | 0.9 | 1.5 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Last visit on treatment (n=109,30,93,29,100,30) | Change at DC Week 1 (n=109,30,93,28,99,30) | Change at DC Week 2 (n=107,29,84,26,94,30) | |
| Lorazepam, Lorazepam | 5.6 | 3.0 | 2.2 |
| Lorazepam, Placebo | 5.5 | 0.3 | 0.6 |
| Pregabalin High Dose, Placebo | 5.5 | -0.0 | -0.8 |
| Pregabalin High Dose, Pregabalin High Dose | 6.3 | 1.6 | 2.5 |
| Pregabalin Low Dose, Placebo | 8.3 | 0.6 | 1.5 |
| Pregabalin Low Dose, Pregabalin Low Dose | 5.6 | 0.7 | 1.2 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Last visit on treatment (n=15,18,20) | Change at Discontinuation Week 1 (n=15,18,18) | |
| Lorazepam | 13.1 | -4.2 |
| Pregabalin High Dose | 10.1 | 0.1 |
| Pregabalin Low Dose | 16.8 | -2.8 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Last visit on treatment | Change at Discontinuation Week 1 | |
| Lorazepam | 5.0 | 2.3 |
| Pregabalin High Dose | 7.2 | 1.9 |
| Pregabalin Low Dose | 6.5 | 1.4 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Last visit on treatment | Change at Discontinuation Week 1 | |
| Lorazepam, Lorazepam | 5.3 | 3.0 |
| Lorazepam, Placebo | 4.7 | -0.1 |
| Pregabalin High Dose, Placebo | 4.9 | 0.0 |
| Pregabalin High Dose, Pregabalin High Dose | 5.2 | 1.7 |
| Pregabalin Low Dose, Placebo | 6.5 | 1.0 |
| Pregabalin Low Dose, Pregabalin Low Dose | 3.9 | 1.1 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Lorazepam | 4.4 | 2.3 |
| Pregabalin High Dose | 4.6 | 2.3 |
| Pregabalin Low Dose | 4.5 | 2.5 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected (NCT00624780)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Lorazepam, Lorazepam | 4.4 | 1.9 |
| Lorazepam, Placebo | 4.5 | 2.4 |
| Pregabalin High Dose, Placebo | 4.5 | 2.2 |
| Pregabalin High Dose, Pregabalin High Dose | 4.7 | 2.3 |
| Pregabalin Low Dose, Placebo | 4.5 | 2.5 |
| Pregabalin Low Dose, Pregabalin Low Dose | 4.5 | 2.1 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=15,19,18) | Discontinuation Week 2 (n=14,15,16) | |
| Lorazepam | 14.1 | 14.6 |
| Pregabalin High Dose | 18.1 | 13.9 |
| Pregabalin Low Dose | 19.0 | 18.6 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=58,52,48) | Discontinuation Week 2 (n=54,49,44) | |
| Lorazepam | 8.8 | 8.3 |
| Pregabalin High Dose | 9.6 | 9.0 |
| Pregabalin Low Dose | 9.4 | 9.9 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=109,30,94,28,99,30) | Discontinuation Week 2 (n=107,29,84,26,94,30) | |
| Lorazepam, Lorazepam | 8.4 | 7.9 |
| Lorazepam, Placebo | 7.07 | 6.1 |
| Pregabalin High Dose, Placebo | 5.5 | 5.0 |
| Pregabalin High Dose, Pregabalin High Dose | 7.9 | 8.9 |
| Pregabalin Low Dose, Placebo | 8.4 | 9.2 |
| Pregabalin Low Dose, Pregabalin Low Dose | 6.3 | 6.5 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Lorazepam | 24.5 | 7.9 |
| Pregabalin High Dose | 25.3 | 8.0 |
| Pregabalin Low Dose | 24.9 | 8.9 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Lorazepam, Lorazepam | 24.7 | 5.7 |
| Lorazepam, Placebo | 24.1 | 6.6 |
| Pregabalin High Dose, Placebo | 24.6 | 7.1 |
| Pregabalin High Dose, Pregabalin High Dose | 25.6 | 7.0 |
| Pregabalin Low Dose, Placebo | 25.1 | 10.2 |
| Pregabalin Low Dose, Pregabalin Low Dose | 24.8 | 6.5 |
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | participants (Number) | |
|---|---|---|
| Newly developed DESS | Worsened DESS | |
| Lorazepam | 3 | 0 |
| Pregabalin High Dose | 6 | 0 |
| Pregabalin Low Dose | 0 | 0 |
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | participants (Number) | |
|---|---|---|
| Newly developed DESS | Worsened DESS | |
| Lorazepam | 36 | 1 |
| Pregabalin High Dose | 40 | 1 |
| Pregabalin Low Dose | 38 | 2 |
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | participants (Number) | |
|---|---|---|
| Newly developed DESS | Worsened DESS | |
| Lorazepam, Lorazepam | 50 | 5 |
| Lorazepam, Placebo | 7 | 0 |
| Pregabalin High Dose, Placebo | 5 | 0 |
| Pregabalin High Dose, Pregabalin High Dose | 78 | 2 |
| Pregabalin Low Dose, Placebo | 17 | 1 |
| Pregabalin Low Dose, Pregabalin Low Dose | 35 | 2 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and Week 12, for period 1, and between Week 13 and Week 24, for period 2, that were absent before treatment or that worsened relative to pretreatment state. (NCT00624780)
Timeframe: Baseline up to Week 12 (period 1), Week 13 up to Week 24 (period 2)
| Intervention | participants (Number) | |
|---|---|---|
| Period 1 (n=154,52,154,52,153,50) | Period 2 (n=121,39,112,38,114,39) | |
| Lorazepam, Lorazepam | 95 | 52 |
| Lorazepam, Placebo | 35 | 20 |
| Pregabalin High Dose, Placebo | 37 | 26 |
| Pregabalin High Dose, Pregabalin High Dose | 103 | 62 |
| Pregabalin Low Dose, Placebo | 40 | 18 |
| Pregabalin Low Dose, Pregabalin Low Dose | 100 | 62 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=15,19,18) | Discontinuation Week 2 (n=14,15,16) | |
| Lorazepam | 9.1 | 10.6 |
| Pregabalin High Dose | 10.2 | 8.2 |
| Pregabalin Low Dose | 14.3 | 14.1 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=58,52,49) | Discontinuation Week 2 (n=54,49,44) | |
| Lorazepam | 7.3 | 6.9 |
| Pregabalin High Dose | 9.1 | 8.9 |
| Pregabalin Low Dose | 8.0 | 8.3 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=109,30,94,29,99,30) | Discontinuation Week 2 (n=106,29,84,26,93,30) | |
| Lorazepam, Lorazepam | 8.0 | 7.1 |
| Lorazepam, Placebo | 4.6 | 4.6 |
| Pregabalin High Dose, Placebo | 4.9 | 4.1 |
| Pregabalin High Dose, Pregabalin High Dose | 6.8 | 7.9 |
| Pregabalin Low Dose, Placebo | 7.4 | 7.1 |
| Pregabalin Low Dose, Pregabalin Low Dose | 5.1 | 5.7 |
"Assess anxiety by hospital anxiety depression scale survey~This 14-component scoring system is used to tabulate a total sum score (0-42) or separate anxiety and depression scores (0-21). A higher score represents a more severe degree of anxiety and/or depression. The severity of a patient's anxiety or depression may then be grouped into three categories based on the score (Normal, 0-7; Borderline abnormal, 8-10; Abnormal 11-21)." (NCT03093454)
Timeframe: Pre-operatively, Post-op Day 1 (POD1), Final Post-op Day (Final POD)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Pre-operative | Post-op Day 1 (POD1) | Final Post-op Day (Final POD) | |
| Control Group | 14.9 | 14.8 | 15.8 |
| Lavender Group | 14.4 | 15.0 | 15.7 |
"Assess pain through pain scores documented in medical record compared to control group.~Pain score of 0 is no pain versus pain score of 10 is highest pain possible." (NCT03093454)
Timeframe: Pre-operatively, Post-op Day 1 (POD1), and final post-op day (final POD)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Preoperative | Post-op Day 1 (POD1) | Final Post-op Day (final POD) | |
| Control Group | 0.5 | 3.5 | 2.5 |
| Lavender Group | 0.9 | 3.1 | 2.9 |
Assess sleep quality by Richards Campbell sleep questionnaire survey A score of zero (0) minimal if any sleep at all versus 10 deep and sound sleeping during hospital stay. (NCT03093454)
Timeframe: Pre-operatively, Post-op Day 1(POD1), and final Post-op Day (final POD)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Pre-operative | Post-op Day 1 (POD1) | Final Post-op Day (Final POD) | |
| Control Group | 6.5 | 5.5 | 6.6 |
| Lavender Group | 5.6 | 5.1 | 7.4 |
Measured the level of a participant's depression; 0 - 48; higher scores worse (NCT00662259)
Timeframe: 0, 7, 28 days
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 0 (Baseline) | Day 7 | Day 28 | |
| Alprazolam | 12.42 | 8.05 | 6.42 |
| Placebo | 12.09 | 10.09 | 9.09 |
Measured participant's general anxiety; range 0 - 56; higher scores worse (NCT00662259)
Timeframe: 0, 7, 28 days
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 0 (Baseline) | Day 7 | Day 28 | |
| Alprazolam | 27.79 | 13.58 | 10.85 |
| Placebo | 28.00 | 22.18 | 20.18 |
Measured participant's extent of worry; range 16 - 80, higher scores worse (NCT00662259)
Timeframe: 0, 7, 28 days
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 0 (Baseline) | Day 7 | Day 28 | |
| Alprazolam | 64.74 | 50.26 | 48.11 |
| Placebo | 66.73 | 62.45 | 61.36 |
Extent of activation a brain signal when matching emotional face expressions as a percentage of the brain signal when matching geometric designs. The brain signal is the blood oxygen level dependent signal measured by functional magnetic resonance imaging. (NCT00662259)
Timeframe: 0,1,28 days
| Intervention | Percent signal change in brain acitivity (Mean) | ||
|---|---|---|---|
| Day 0 (Baseline) | Day 1 | Day 28 | |
| Alprazolam | .1489 | .0119 | .1230 |
| Placebo | .1074 | .1404 | .1699 |
Extent of activation of a brain signal when anticipating the viewing of an emotional picture as a percentage of brain signal when the viewing of an emotional signal is not anticipated. The brain signal is the blood oxygen level dependent signal as measured by functional magnetic resonance imaging. (NCT00662259)
Timeframe: 0,1,28 days
| Intervention | Percent signal change in brain acitivity (Mean) | ||
|---|---|---|---|
| Day 0 (Baseline) | Day 1 | Day 28 | |
| Alprazolam | .0707 | .0458 | .0596 |
| Placebo | .0724 | .0645 | .0461 |
7 reviews available for lorazepam and Anxiety Neuroses
| Article | Year |
|---|---|
Pharmacologic predictors of benzodiazepine response trajectory in anxiety disorders: a Bayesian hierarchical modeling meta-analysis.
Topics: Adult; Anxiety; Anxiety Disorders; Bayes Theorem; Benzodiazepines; Humans; Lorazepam | 2023 |
Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Capsules; Humans; Lavandula; Lorazepam; Network Meta-Analysi | 2019 |
Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Humans; Lavandula; Lorazepam; Oils, Volatile; Personality In | 2010 |
The effects of benzodiazepines on cognition.
Topics: Activities of Daily Living; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Cognition; Cogn | 2005 |
Lorazepam: a review of its clinical pharmacological properties and therapeutic uses.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Central Nervous System; Clinical Trials as Topic; Diazepam; | 1981 |
Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone.
Topics: Ambulatory Care; Anxiety Disorders; Buspirone; Double-Blind Method; Female; Humans; Lorazepam; Male; | 1990 |
Review of the side-effect profile of buspirone.
Topics: Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as T | 1986 |
49 trials available for lorazepam and Anxiety Neuroses
| Article | Year |
|---|---|
Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Dose-Response Relationship, Drug; D | 2014 |
Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study.
Topics: Adult; Alcoholism; Anxiety Disorders; Craving; Depressive Disorder, Major; Disulfiram; Drug Therapy, | 2016 |
Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Female; Humans; Lorazepam; Male; | 2009 |
A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Female; Humans; Lavandula; | 2010 |
One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Attention; Cerebral Cortex; Cross-Over Studi | 2011 |
Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Female; Humans; Lorazepam; Male; | 2013 |
Therapeutic effectiveness of Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Female; Galphimia; Humans; Kidne | 2012 |
[Spectrum of therapeutic efficacy and safety of Lorafen (lorazepam) use for anxiety disorders].
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Chronic Disease; Female; Humans; Lo | 2003 |
Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing.
Topics: Adolescent; Adult; Amygdala; Anti-Anxiety Agents; Anxiety Disorders; Cerebral Cortex; Dose-Response | 2005 |
Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing.
Topics: Adolescent; Adult; Amygdala; Anti-Anxiety Agents; Anxiety Disorders; Cerebral Cortex; Dose-Response | 2005 |
Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing.
Topics: Adolescent; Adult; Amygdala; Anti-Anxiety Agents; Anxiety Disorders; Cerebral Cortex; Dose-Response | 2005 |
Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing.
Topics: Adolescent; Adult; Amygdala; Anti-Anxiety Agents; Anxiety Disorders; Cerebral Cortex; Dose-Response | 2005 |
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers.
Topics: Administration, Inhalation; Adult; Anti-Anxiety Agents; Anxiety Disorders; Carbon Dioxide; Double-Bl | 2007 |
Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind | 2007 |
A comparison of prazepam, diazepam, lorazepam and placebo in anxious outpatients in non-psychiatric private practices.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Depressive Disorder; Diazepam; Doub | 1981 |
Lorazepam: a review of its clinical pharmacological properties and therapeutic uses.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Central Nervous System; Clinical Trials as Topic; Diazepam; | 1981 |
A double-blind study of alprazolam and lorazepam in the treatment of anxiety.
Topics: Adolescent; Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Clinical Tri | 1983 |
Intramuscular lorazepam. A double-blind comparison with diazepam and placebo.
Topics: Adolescent; Adult; Anxiety Disorders; Clinical Trials as Topic; Diazepam; Double-Blind Method; Femal | 1983 |
[Treatment of anxiety with prazepam, 40 mg. A controlled study versus lorazepam].
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Clinical Trials as Topic; Double-Blind Method; Female; H | 1984 |
Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study.
Topics: Adult; Anxiety Disorders; Buspirone; Double-Blind Method; Female; Humans; Lorazepam; Male; Middle Ag | 1995 |
Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Attention; Automobile Driving; Cross-Over Studies; Diazepam; | 1995 |
The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Female; Humans; Lorazepam; Male; | 1993 |
A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Female; Humans; Lorazepam; Male; | 1993 |
Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Double-Blind Method; Fem | 1995 |
Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Female; Humans; Lorazepam; Male; Placebo Effect; Psyc | 1995 |
Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping meth
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Arousal; Attention; Brain Mapping; Cerebral Cor | 1997 |
Comparative studies on the effects of the combination drug lorazepam plus diphenhydramine (Somnium) versus lorazepam on the noopsyche, thymopsyche and psychophysiology in nonorganic insomnia related to generalized anxiety disorder.
Topics: Adult; Aged; Anxiety Disorders; Diphenhydramine; Discriminant Analysis; Double-Blind Method; Drug Co | 1997 |
Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Double-Blind Method; Female; Humans; Loraz | 1998 |
Effects of lorazepam on emotional reactivity, performance, and vigilance in subjects with high or low anxiety.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Arousal; Attention; Dose-Response Relationship, Drug; | 2000 |
A double-blind controlled therapeutic trial of lorazepam vs medazepam in psychosomatic conditions in general practice.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as Topic; Family Pr | 1975 |
Proceedings: Lorazepam in the treatment of neurosis--an uncontrolled clinical study.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as Topic; Female; Humans; Lorazepam; | 1976 |
Intravenous lorazepam in the acute anxiety crisis: a preliminary report on 60 cases.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as T | 1976 |
A test of the concept of "underlying depressive illness" in the treatment of anxiety states.
Topics: Adjustment Disorders; Adult; Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as Topic; Drug | 1976 |
Double-blind cross-over clinical comparison of two 2'-chloro benzodiazepines: 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (chlordesmethyldiazepam) versus 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one (
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Brief Psychiatric Rating Scale; Clinical Trials | 1977 |
Clinical assessment of the safety and efficacy of lorazepam, a new benzodiazepine derivative, in the treatment of anxiety.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Anti-Anxiety Agents; Anxiety Disorders; Do | 1978 |
Studies with oral lorazepam in anxiety neurosis associated with depressive symptomatology.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Depression; D | 1978 |
Antianxiety effects of lorazepam in patients with cardiovascular symptomatology.
Topics: Administration, Oral; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Cardiovascular Diseases; | 1978 |
Clinical assessment of lorazepam in anxiety: a double-blind study.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as Topic; Drug Evaluation; Female; Hu | 1975 |
Alpidem and lorazepam in the treatment of patients with anxiety disorders: comparison of physiological and psychological effects.
Topics: Adult; Analysis of Variance; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Electroenc | 1992 |
A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Doubl | 1990 |
Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone.
Topics: Ambulatory Care; Anxiety Disorders; Buspirone; Double-Blind Method; Female; Humans; Lorazepam; Male; | 1990 |
Discrimination of mode of action of anxiolytics using an integrated computer data bank and Dynamic Brain Mapping (CNS effects of diazepam and lorazepam).
Topics: Adult; Anxiety Disorders; Brain; Brain Mapping; Central Nervous System; Diazepam; Double-Blind Metho | 1989 |
Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Double-Blind Method; Fear; Humans; Lorazepam; Panic; Ran | 1989 |
Efficacy and withdrawal of two potent benzodiazepines: bromazepam and lorazepam.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Bromazepam; Clinical Trials as Topic; Double-Blind Me | 1985 |
A multi-centre, double-blind parallel trial of bromazepam ('Lexotan') and lorazepam to compare the acute benefit-risk ratio in the treatment of patients with anxiety.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Bromazepam; Clinical Trials as Topic; Double-Bl | 1985 |
Review of the side-effect profile of buspirone.
Topics: Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as T | 1986 |
Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
Topics: Adolescent; Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; C | 1986 |
Antianxiety properties of lormetazepam. A double-blind crossover trial versus diazepam.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Clinical Trials as Topic; Diazepam; | 1986 |
Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Bromazepam; Double-Blind Method; Humans; | 1986 |
Clorazepate and lorazepam: clinical improvement and rebound anxiety.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as Topic; Clorazepate Dipotassium; Do | 1988 |
Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Double-Blind Method; Female; Humans; Lorazepam; Male; Pi | 1987 |
The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam.
Topics: Adult; Anxiety Disorders; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Lorazepam; | 1985 |
44 other studies available for lorazepam and Anxiety Neuroses
| Article | Year |
|---|---|
Brief psychotic disorder associated with quarantine and mild COVID-19.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; COVID-19; Humans; Lorazepam; Ma | 2020 |
Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Dose-Response Relationship, Drug; Escape Reaction; Fear; Fem | 2013 |
[Description of a patient with schizophrenia and coexisting megadose lorazepam dependence with slightly expressed withdrawl symptoms during drug reduction. A case report].
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Humans; Lorazepam; Male; Schizophrenia, Paranoid; Sub | 2012 |
Old dog, new tricks: treating co-occurring anxiety and alcohol use disorders.
Topics: Alcohol-Related Disorders; Alcoholism; Anxiety; Anxiety Disorders; Disulfiram; Humans; Lorazepam; Pi | 2016 |
Socio-demographic and clinical characteristics of benzodiazepine long-term users: Results from a tertiary care center.
Topics: Adult; Anxiety Disorders; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Long-Te | 2016 |
Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.
Topics: Adolescent; Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Dose-Response Relationship, D | 2010 |
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
Topics: Adult; Anxiety Disorders; Female; Humans; Lorazepam; Male; Middle Aged; Paroxetine; Psychometrics; R | 2010 |
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
Topics: Adult; Anxiety Disorders; Female; Humans; Lorazepam; Male; Middle Aged; Paroxetine; Psychometrics; R | 2010 |
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
Topics: Adult; Anxiety Disorders; Female; Humans; Lorazepam; Male; Middle Aged; Paroxetine; Psychometrics; R | 2010 |
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
Topics: Adult; Anxiety Disorders; Female; Humans; Lorazepam; Male; Middle Aged; Paroxetine; Psychometrics; R | 2010 |
Cases of catatonia on an academic electroconvulsive therapy service: lessons to learn.
Topics: Aged; Aged, 80 and over; Anxiety Disorders; Catatonia; Depressive Disorder; Depressive Disorder, Maj | 2011 |
Musical hallucinations during a treatment with benzodiazepine.
Topics: Amitriptyline; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Depressive Disorder; Dose-Re | 2002 |
How to ensure clinical trial sensitivity in psychotropic drug development: a case study.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials, Phase II as Topic; Control Groups; Drugs, I | 2005 |
Conclusions inconsistent with results with citalopram.
Topics: Age Factors; Anxiety Disorders; Citalopram; Double-Blind Method; Drug Administration Schedule; Drug | 2005 |
[Effect of Lorazepam on emotional status and quality of life of patients with ischemic heart disease].
Topics: Adult; Affect; Aged; Anti-Anxiety Agents; Anxiety Disorders; Female; Humans; Lorazepam; Male; Middle | 2006 |
Development and evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Female; Focus Groups; Health Status; Humans; Kaplan-M | 2008 |
GABA(A) versus GABA(B) in catatonia.
Topics: Anxiety Disorders; Catatonia; Chest Pain; Delirium; GABA Modulators; Humans; Lorazepam; Male; Middle | 2007 |
[Lorazepam. Evaluation after extensive use].
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Bipolar Disorder; Depressive Disorder; Dogs; Humans | 1981 |
The place of anxiety in depressive symptomatology.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Clorazepate Dipotas | 1983 |
Clinical aspects of chronic use of alprazolam and lorazepam.
Topics: Alprazolam; Ambulatory Care; Anxiety Disorders; Depressive Disorder; Drug Administration Schedule; F | 1995 |
[Digestive symptoms in the course of benzodiazepine withdrawal syndrome].
Topics: Anxiety Disorders; Bromazepam; Diarrhea; Drug Therapy, Combination; Female; Gastrointestinal Motilit | 1994 |
Alcohol and benzodiazepines generate anxiety, panic and phobias.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Anxiety Disorders; Diazepam; Female; | 1995 |
Organic anxiety syndrome after withdrawal of atenolol.
Topics: Aged; Anxiety Disorders; Atenolol; Diltiazem; Humans; Hypertension; Lorazepam; Male; Substance Withd | 1994 |
Detection and quantification of lorazepam in human hair by GC-MS/NCI in a case of traffic accident.
Topics: Accidents, Traffic; Anti-Anxiety Agents; Anxiety Disorders; Dose-Response Relationship, Drug; Gas Ch | 1996 |
Brief acute psychosis following hysterectomy in ethnopsychiatric context.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; China; Culture; | 2000 |
Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Anxiety Disorders; Dopamine; Dose-Response Relationship, D | 2001 |
De novo absence status of late onset following withdrawal of lorazepam: a case report.
Topics: Age of Onset; Aged; Anti-Anxiety Agents; Anxiety Disorders; Confusion; Diagnosis, Differential; Elec | 2001 |
Anxiety therapy in the neoplastic patient.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Female; Humans; Lorazepam; Male; Middl | 1976 |
Lorazepam in the treatment of neurosis.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Drug Tolerance; Female; Humans; Lorazepam | 1976 |
Management of acute anxiety syndrome with parenterally administered lorazepam.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Female; Humans; Hysteria; | 1978 |
Clinical profile of lorazepam, a new benzodiazepine tranquilizer.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Anti-Anxiety Agents; Anxiety; Anxiety Di | 1978 |
[An evaluation of lorazépam (temesta) in out-patient practice (author's transl)].
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Drug Evaluation; Female; Humans; Lorazepam; Mal | 1978 |
Is lorazepam really different?
Topics: Anti-Anxiety Agents; Anxiety Disorders; Half-Life; Humans; Lorazepam | 1979 |
Treatment of 'brain fag' syndrome.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Depression; Humans; Lorazepam; Male; Nige | 1975 |
Lorazepam, amitriptyline, and sulpiride: withdrawal effects.
Topics: Amitriptyline; Anxiety Disorders; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Lo | 1991 |
Pharmacologic approach to sleep panic attacks.
Topics: Adult; Anxiety Disorders; Fear; Female; Humans; Imipramine; Lithium; Lithium Carbonate; Lorazepam; P | 1990 |
The diagnosis and treatment of panic disorder in alcoholics: three cases.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety Disorders; Clonazepam; Diazepam; Follow-Up Studies; Hum | 1990 |
Clonazepam in the treatment of obsessive compulsive disorder associated with panic disorder in one patient.
Topics: Adult; Anxiety Disorders; Clonazepam; Fear; Humans; Lorazepam; Male; Obsessive-Compulsive Disorder; | 1989 |
Depression in patients receiving lorazepam for panic.
Topics: Anxiety Disorders; Depressive Disorder; Fear; Humans; Lorazepam; Panic | 1989 |
Delusional depression following benzodiazepine withdrawal.
Topics: Adult; Anxiety Disorders; Delusions; Depressive Disorder; Diazepam; Female; Humans; Lorazepam; Male; | 1988 |
Complete loss of libido with short-term use of lorazepam.
Topics: Adult; Anxiety Disorders; Humans; Libido; Lorazepam; Male; Middle Aged; Sexual Dysfunctions, Psychol | 1988 |
Manic-like reaction induced by lorazepam withdrawal.
Topics: Anxiety Disorders; Bipolar Disorder; Female; Humans; Lorazepam; Middle Aged; Sleep Initiation and Ma | 1987 |
Orofacial dyskinesias associated with lorazepam therapy.
Topics: Anxiety Disorders; Depressive Disorder; Dyskinesia, Drug-Induced; Facial Muscles; Female; Humans; Lo | 1986 |
A case of alprazolam, but not lorazepam, inducing manic symptoms.
Topics: Adult; Alprazolam; Anxiety Disorders; Bipolar Disorder; Female; Humans; Lorazepam; Panic | 1987 |
A controlled trial of treatments for generalized anxiety.
Topics: Adult; Anxiety Disorders; Behavior Therapy; Chronic Disease; Cognition; Female; Follow-Up Studies; H | 1987 |
Emergency treatment of acute psychosis, agitation, and anxiety.
Topics: Anxiety Disorders; Diazepam; Droperidol; Emergencies; Haloperidol; Humans; Lorazepam; Panic; Propran | 1985 |
Panics, prolapse, and PVCs.
Topics: Adult; Anxiety Disorders; Arrhythmias, Cardiac; Diagnosis, Differential; Fear; Female; Humans; Imipr | 1985 |